Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Expert Opinion on Investigational Drugs
|
November 4, 2000
Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock
M Eriksson, S Basu, A Larsson, et al.
Journal of Cardiovascular Pharmacology
|
August 1, 1990
Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6-173) in a canine model
Z Wu, F Van de Werf, T Stassen, et al.
Journal of Cardiovascular Pharmacology
|
March 26, 1998
Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery
J L Mehta, L Chen, W W Nichols, et al.
Journal of Pharmacological and Toxicological Methods
|
August 7, 1998
Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran
Y Uriuda, Q D Wang, N Hatori, et al.
British Journal of Pharmacology
|
November 6, 2007
The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro
N J Mutch, N R Moore, C Mattsson, et al.
Journal of Internal Medicine
|
September 12, 2006
Cognitive-behavioural stress management does not improve biological cardiovascular risk indicators in women with ischaemic heart disease: a randomized-controlled trial
M Claesson, L S Birgander, J-H Jansson, et al.
Thrombosis and Haemostasis
|
May 15, 2002
Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran)
C Mattsson, J A Björkman, T Abrahamsson, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 1, 1996
Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis
L Chen, W W Nichols, C Mattsson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 1, 1985
Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs
K M Brinkhous, H Sandberg, J B Garris, et al.
Arzneimittel-Forschung
|
May 1, 1995
Inhibition of smooth muscle cell proliferation and neointimal growth by low-anticoagulant heparin
W Völker, A Böhm, A Schmidt, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Expert Opinion on Investigational Drugs
|
November 4, 2000
Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock
M Eriksson, S Basu, A Larsson, et al.
Journal of Cardiovascular Pharmacology
|
August 1, 1990
Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6-173) in a canine model
Z Wu, F Van de Werf, T Stassen, et al.
Journal of Cardiovascular Pharmacology
|
March 26, 1998
Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery
J L Mehta, L Chen, W W Nichols, et al.
Journal of Pharmacological and Toxicological Methods
|
August 7, 1998
Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran
Y Uriuda, Q D Wang, N Hatori, et al.
British Journal of Pharmacology
|
November 6, 2007
The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro
N J Mutch, N R Moore, C Mattsson, et al.
Journal of Internal Medicine
|
September 12, 2006
Cognitive-behavioural stress management does not improve biological cardiovascular risk indicators in women with ischaemic heart disease: a randomized-controlled trial
M Claesson, L S Birgander, J-H Jansson, et al.
Thrombosis and Haemostasis
|
May 15, 2002
Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran)
C Mattsson, J A Björkman, T Abrahamsson, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 1, 1996
Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis
L Chen, W W Nichols, C Mattsson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 1, 1985
Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs
K M Brinkhous, H Sandberg, J B Garris, et al.
Arzneimittel-Forschung
|
May 1, 1995
Inhibition of smooth muscle cell proliferation and neointimal growth by low-anticoagulant heparin
W Völker, A Böhm, A Schmidt, et al.
Page
of 5